Source link : https://www.newshealth.biz/health-news/ema-backs-oral-drug-for-primary-biliary-cholangitis/
The European Medicines Agency (EMA) has recommended that a conditional marketing authorization should be granted for Iqirvo (elafibranor; Ipsen Pharma) for treating primary biliary cholangitis (PBC). PBC is a rare, chronic disease in which the body’s immune system mistakenly attacks the interlobular bile ducts in the liver. These ducts become inflamed, and cirrhosis, liver failure, […]
Author : News Health
Publish date : 2024-07-26 14:04:13
Copyright for syndicated content belongs to the linked Source.
Categories